Skip to main content

Table 3 The association between bcl-2 and other markers

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

   Bcl-2 expression P
   (-) (+)  
Histology ductal 55 (39.9) 83 (60.1) 0.521
  others 4 (30.8) 9 (69.2)  
Histologic grade I, II 14 (21.2) 52 (78.8) < 0.001
  III 42 (54.5) 35 (45.5)  
Endolymphatic tumor emboli absent 2 (33.3) 4 (66.7) 1.000
  present 43 (37.1) 73 (62.9)  
ER (-) 52 (76.5) 16 (23.5) < 0.001
  (+) 7 (8.4) 76 (91.6)  
PR (-) 55 (59.8) 37 (40.2) < 0.001
  (+) 4 (6.8) 55 (93.2)  
p53 ≤25% 33 (31.4) 72 (68.6) 0.004
  >25% 26 (56.5) 20 (43.5)  
c-erbB2 (-)~(2+) 42 (34.7) 79 (65.3) 0.027
  (3+) 17 (56.7) 13 (43.3)  
Ki-67 < 5% 18 (26.9) 49 (73.1) 0.006
  ≥5% 41 (48.8) 43 (51.2)  
  1. n (%) patients for each variable. P-values were obtained using the chi-square test.